PMID- 21128900
OWN - NLM
STAT- MEDLINE
DCOM- 20110506
LR  - 20231213
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 16
IP  - 33
DP  - 2010
TI  - Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.
PG  - 3656-60
AB  - Over the last 15 years, the use of various biological therapies has largely 
      improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). 
      Blockade of cytokine synthesis and/or activity is at the forefront of this new 
      era with the success of inhibitors of tumor necrosis factor (TNF)-alpha. These 
      therapies are however not effective in all IBD patients and efficacy may wane. 
      Moreover, patients treated with anti-TNF-alpha antibodies can develop severe 
      side-effects and new immune-mediated diseases. Therefore, a new challenge is to 
      elucidate new inflammatory networks in the IBD tissue and develop novel 
      anti-cytokine compounds, which may act in patients who are resistant to or cannot 
      receive anti-TNF-alpha therapies. In this article we review the available data 
      supporting the pathogenic role of IL-23 and Th17-related cytokines in IBD, and 
      discuss whether and how compounds that control the activity of these cytokines 
      may enter into the therapeutic armamentarium of IBD.
FAU - De Nitto, Daniela
AU  - De Nitto D
AD  - Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 
      00133 Rome, Italy.
FAU - Sarra, Massimiliano
AU  - Sarra M
FAU - Cupi, Maria Laura
AU  - Cupi ML
FAU - Pallone, Francesco
AU  - Pallone F
FAU - Monteleone, Giovanni
AU  - Monteleone G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Cytokines)
RN  - 0 (IL17A protein, human)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-23)
RN  - 0 (Interleukins)
SB  - IM
MH  - Animals
MH  - Colitis, Ulcerative/drug therapy/metabolism
MH  - Crohn Disease/drug therapy/metabolism
MH  - Cytokines/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Inflammatory Bowel Diseases/*drug therapy/metabolism
MH  - Interleukin-17/antagonists & inhibitors/metabolism
MH  - Interleukin-23/*antagonists & inhibitors/metabolism
MH  - Interleukins/agonists/metabolism
MH  - Molecular Targeted Therapy
MH  - Th17 Cells/*drug effects/*metabolism
MH  - Interleukin-22
EDAT- 2010/12/07 06:00
MHDA- 2011/05/07 06:00
CRDT- 2010/12/07 06:00
PHST- 2010/10/16 00:00 [received]
PHST- 2010/11/10 00:00 [accepted]
PHST- 2010/12/07 06:00 [entrez]
PHST- 2010/12/07 06:00 [pubmed]
PHST- 2011/05/07 06:00 [medline]
AID - BSP/CPD/E-Pub/000268 [pii]
AID - 10.2174/138161210794079164 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2010;16(33):3656-60. doi: 10.2174/138161210794079164.